MCID: CRD137
MIFTS: 54

Cardiogenic Shock

Categories: Blood diseases, Cardiovascular diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Cardiogenic Shock

MalaCards integrated aliases for Cardiogenic Shock:

Name: Cardiogenic Shock 58 63 75 31
Shock, Cardiogenic 71
Shock Cardiogenic 53

Characteristics:


Prevelance:

1-5/10000 (Europe) 58

Age Of Onset:

Adolescent,Adult,Childhood,Elderly 58

Classifications:



Summaries for Cardiogenic Shock

PubMed Health : 63 Cardiogenic shock: Cardiogenic (kar-dee-oh-JE-nik) shock is a condition in which a suddenly weakened heart isn't able to pump enough blood to meet the body's needs. The condition is a medical emergency and is fatal if not treated right away. The most common cause of cardiogenic shock is damage to the heart muscle from a severe heart attack. However, not everyone who has a heart attack has cardiogenic shock. In fact, on average, only about 7 percent of people who have heart attacks develop the condition. If cardiogenic shock does occur, it's very dangerous. When people die from heart attacks in hospitals, cardiogenic shock is the most common cause of death.

MalaCards based summary: Cardiogenic Shock, also known as shock, cardiogenic, is related to mitral valve insufficiency and myocardial infarction, and has symptoms including syncope and shock without mention of trauma. An important gene associated with Cardiogenic Shock is NPPB (Natriuretic Peptide B), and among its related pathways/superpathways are MicroRNAs in cardiomyocyte hypertrophy and NO/cGMP/PKG mediated neuroprotection. The drugs Benzocaine and Tannic acid have been mentioned in the context of this disorder. Affiliated tissues include heart, skeletal muscle and kidney, and related phenotypes are hypotension and low-output congestive heart failure

Orphanet: 58 A rare, cardiac condition characterized by severely decreased cardiac output, hypoperfusion and end-organ dysfunction, in the presence of adequate intravascular volume. The clinical presentation is variable and may range from subtle hemodynamic alterations to overt cardiovascular collapse. Commonly reported features include dyspnea, crackles, elevated jugular venous pressure, altered mental state, abnormal pulse pressure, oliguria, cold extremities, and increased serum lactate levels.

Wikipedia: 75 Cardiogenic shock (CS) is a medical emergency resulting from inadequate blood flow due to the... more...

Related Diseases for Cardiogenic Shock

Diseases related to Cardiogenic Shock via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 545)
# Related Disease Score Top Affiliating Genes
1 mitral valve insufficiency 31.4 NPPB NPPA
2 myocardial infarction 31.3 PLAT PIK3C2A NPPB NPPA
3 heart septal defect 31.1 NPPB NPPA
4 acute myocardial infarction 30.9 PLAT PIK3C2A NPPB NPPA
5 myocarditis 30.9 PIK3C2A NPPB NPPA
6 aortic valve disease 2 30.8 NPPB NPPA
7 acute kidney failure 30.7 PIK3C2A NPPA
8 pulmonary edema 30.7 PIK3C2A NPPB NPPA
9 atrioventricular block 30.6 PIK3C2A NPPB
10 pulmonary embolism 30.6 PLAT NPPB
11 coronary artery vasospasm 30.5 PIK3C2A NPPB
12 ventricular septal defect 30.5 NPPB NPPA
13 tricuspid valve insufficiency 30.5 PLAT NPPB
14 heart valve disease 30.5 NPPB NPPA
15 coronary stenosis 30.4 PIK3C2A NPPB
16 endocarditis 30.3 PLAT PIK3C2A
17 cardiac tamponade 30.3 PLAT PIK3C2A NPPB
18 angina pectoris 30.3 PLAT PIK3C2A NPPB
19 transient cerebral ischemia 30.3 PLAT NPPB
20 myxedema 30.2 PIK3C2A NPPA
21 mitral valve stenosis 30.2 PLAT NPPB NPPA
22 inferior myocardial infarction 30.1 PLAT PIK3C2A NPPB
23 pericardial effusion 30.1 PIK3C2A NPPB NPPA
24 disseminated intravascular coagulation 30.0 PLAT PIK3C2A
25 atrial fibrillation 30.0 PLAT NPPB NPPA
26 heart disease 30.0 PLAT PIK3C2A NPPB NPPA
27 lipoprotein quantitative trait locus 30.0 PLAT PIK3C2A NPPB NPPA
28 atrial heart septal defect 29.9 PLAT NPPB NPPA
29 acute kidney tubular necrosis 29.9 PIK3C2A NPPA
30 hypoplastic left heart syndrome 29.9 NPPB NPPA
31 toxic myocarditis 29.9 PIK3C2A NPPB
32 acute anterolateral myocardial infarction 29.8 PIK3C2A NPPB
33 malignant hypertension 29.8 NPPB NPPA
34 renovascular hypertension 29.8 NPPB NPPA
35 stroke, ischemic 29.8 PLAT NPPB NPPA
36 mitral valve disease 29.8 NPPB NPPA
37 anterolateral myocardial infarction 29.8 PLAT NPPB NPPA
38 ischemia 29.6 PLAT PIK3C2A NPPB
39 posterior myocardial infarction 29.5 PLAT PIK3C2A
40 cardiovascular system disease 29.5 PLAT NPPB NPPA
41 patent foramen ovale 29.1 PLAT PIK3C2A NPPB NPPA
42 diabetes mellitus 29.1 PLAT PIK3C2A NPPB NPPA
43 coronary artery dissection, spontaneous 11.2
44 scorpion envenomation 11.2
45 ogden syndrome 11.2
46 hantavirus pulmonary syndrome 11.2
47 pleuro-pericardial cyst 11.2
48 cardiac arrest 11.1
49 broken heart syndrome 10.9
50 pheochromocytoma 10.8

Comorbidity relations with Cardiogenic Shock via Phenotypic Disease Network (PDN): (show all 17)


Active Peptic Ulcer Disease Acute Cystitis
Acute Kidney Failure Aortic Valve Disease 1
Cardiac Arrest Chronic Kidney Disease
Deficiency Anemia Familial Atrial Fibrillation
Heart Disease Intermediate Coronary Syndrome
Kidney Disease Mitral Valve Disease
Peripheral Vascular Disease Respiratory Failure
Third-Degree Atrioventricular Block Tricuspid Valve Disease
Ventricular Fibrillation, Paroxysmal Familial, 1

Graphical network of the top 20 diseases related to Cardiogenic Shock:



Diseases related to Cardiogenic Shock

Symptoms & Phenotypes for Cardiogenic Shock

Human phenotypes related to Cardiogenic Shock:

58 30 (show all 27)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 hypotension 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0002615
2 low-output congestive heart failure 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0009805
3 abnormal left ventricular function 30 Hallmark (90%) HP:0005162
4 myocardial infarction 58 30 Frequent (33%) Frequent (79-30%)
HP:0001658
5 dyspnea 58 30 Frequent (33%) Frequent (79-30%)
HP:0002094
6 hypoxemia 58 30 Frequent (33%) Frequent (79-30%)
HP:0012418
7 oliguria 58 30 Frequent (33%) Frequent (79-30%)
HP:0100520
8 cardiac arrest 58 30 Frequent (33%) Frequent (79-30%)
HP:0001695
9 crackles 58 30 Frequent (33%) Frequent (79-30%)
HP:0030830
10 impaired myocardial contractility 58 30 Frequent (33%) Frequent (79-30%)
HP:0006670
11 elevated jugular venous pressure 58 30 Frequent (33%) Frequent (79-30%)
HP:0030848
12 low pulse pressure 58 30 Frequent (33%) Frequent (79-30%)
HP:0030851
13 increased pulmonary capillary wedge pressure 58 30 Frequent (33%) Frequent (79-30%)
HP:0030876
14 mitral regurgitation 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0001653
15 vertigo 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002321
16 increased serum lactate 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002151
17 metabolic acidosis 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0001942
18 confusion 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0001289
19 st segment elevation 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0012251
20 elevated circulating creatinine concentration 30 Occasional (7.5%) HP:0003259
21 coma 58 30 Very rare (1%) Very rare (<4-1%)
HP:0001259
22 right ventricular failure 58 30 Very rare (1%) Very rare (<4-1%)
HP:0001708
23 reduced consciousness/confusion 58 Frequent (79-30%)
24 congestive heart failure 58 Frequent (79-30%)
25 left ventricular dysfunction 58 Very frequent (99-80%)
26 elevated serum creatinine 58 Occasional (29-5%)
27 abnormal ekg 58 Very frequent (99-80%)

UMLS symptoms related to Cardiogenic Shock:


syncope; shock without mention of trauma

MGI Mouse Phenotypes related to Cardiogenic Shock:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.02 NAA10 NPPA NPPB PIK3C2A PLAT

Drugs & Therapeutics for Cardiogenic Shock

PubMed Health treatment related to Cardiogenic Shock: 63

Cardiogenic shock is life threatening and requires emergency medical treatment . The condition usually is diagnosed after a person has been admitted to a hospital for a heart attack . If the person isn't already in a hospital, emergency treatment can start as soon as medical personnel arrive. The first goal of emergency treatment for cardiogenic shock is to improve the flow of blood and oxygen to the body’s organs . Sometimes both the shock and its cause are treated at the same time. For example, doctors may quickly open a blocked blood vessel that's damaging the heart . Often, this can get the patient out of shock with little or no additional treatment .

Drugs for Cardiogenic Shock (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 76)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
2
Tannic acid Approved Phase 4 1401-55-4 16129878 16129778
3
Carbamide peroxide Approved Phase 4 124-43-6
4
Esmolol Approved, Withdrawn Phase 4 103598-03-4, 81147-92-4 59768
5
Abciximab Approved Phase 4 143653-53-6 3815015
6
Racepinephrine Approved, Vet_approved Phase 4 51-43-4, 329-65-7 838 5816
7
Dopamine Approved Phase 4 62-31-7, 51-61-6 681
8
Dobutamine Approved Phase 4 34368-04-2 36811
9
Milrinone Approved Phase 4 78415-72-2 4197
10
Cangrelor Approved Phase 4 163706-06-7 9854012
11
Ticagrelor Approved Phase 4 274693-27-5 9871419
12
Norepinephrine Approved Phase 4 51-41-2 439260
13
Simendan Investigational Phase 4 131741-08-7
14 Adrenergic beta-Antagonists Phase 4
15 Adrenergic beta-1 Receptor Antagonists Phase 4
16 Adrenergic Antagonists Phase 4
17 Bronchodilator Agents Phase 4
18 Anti-Asthmatic Agents Phase 4
19 Respiratory System Agents Phase 4
20 Mydriatics Phase 4
21 Epinephryl borate Phase 4
22 Cardiotonic Agents Phase 4
23 Adrenergic beta-Agonists Phase 4
24 Pharmaceutical Solutions Phase 4
25 Protective Agents Phase 4
26 Phosphodiesterase Inhibitors Phase 4
27 Phosphodiesterase 3 Inhibitors Phase 4
28 Purinergic P2Y Receptor Antagonists Phase 4
29 Tin Fluorides Phase 4
30 Vasoconstrictor Agents Phase 4
31 Neurotransmitter Agents Phase 4
32 Adrenergic Agonists Phase 4
33 Adrenergic Agents Phase 4
34 Sympathomimetics Phase 4
35 Adrenergic alpha-Agonists Phase 4
36 Platelet Aggregation Inhibitors Phase 4
37
Fludrocortisone Approved, Investigational Phase 3 127-31-1 31378
38
Hydrocortisone succinate Approved Phase 3 2203-97-6 3643
39
Hydrocortisone acetate Approved, Vet_approved Phase 3 50-03-3
40
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 3640 5754
41
Nitric Oxide Approved Phase 3 10102-43-9 145068
42
Iodine Approved, Investigational Phase 3 7553-56-2 807
43 Anti-Inflammatory Agents Phase 3
44 Hydrocortisone 17-butyrate 21-propionate Phase 3
45 omega-N-Methylarginine Phase 3
46
Heparin, bovine Approved, Investigational, Withdrawn Phase 2 9005-49-6 22833565 9812414 772
47 Pyruvate Phase 2
48 Anticoagulants Phase 2
49 Fibrinolytic Agents Phase 2
50 Calcium, Dietary Phase 2

Interventional clinical trials:

(show top 50) (show all 163)
# Name Status NCT ID Phase Drugs
1 Effect of Ivabradine on Heart Rate and Hemodynamics in Patients With Stage D Heart Failure (HF)/Cardiogenic Shock on Dobutamine Treatment Unknown status NCT03387605 Phase 4 Ivabradine;Placebo
2 Efficacy and Safety on Heart Rate Control With Ivabradine on Cardiogenic Shock (ES-FISH) Unknown status NCT03437369 Phase 4 Ivabradine Oral Tablet
3 Impact of Early CRRT Intervention in Patients Receiving VA-ECMO Support on 30-day Mortality: A Randomized Controlled Trial Unknown status NCT03549923 Phase 4 Esmolol;Standard care
4 Left Ventricular Assist Device (Impella LP 2.5) vs. Intraaortic Balloon Counterpulsation (IABP) in Patients With Cardiogenic Shock and Acute Coronary Syndromes Completed NCT00417378 Phase 4
5 Randomized Clinical Study of Intraaortic Balloon Pump Use in Cardiogenic Shock Complicating Acute Myocardial Infarction Completed NCT00491036 Phase 4
6 Routine Upfront Abciximab Versus Standard Peri-Procedural Therapy in Patients Undergoing Percutaneous Coronary Intervention for Cardiogenic Shock PRAGUE-7 Trial. Completed NCT00420030 Phase 4 Abciximab
7 Prospective Randomized Multicenter Study Comparing Immediate Multivessel Revascularization by PCI Versus Culprit Lesion PCI With Staged Non-culprit Lesion Revascularization in Patients With Acute Myocardial Infarction Complicated by Cardiogenic Shock Completed NCT01927549 Phase 4
8 Randomized Clinical Study of Extra-Corporal Life Support in Cardiogenic Shock Complicating Acute Myocardial Infarction Completed NCT02544594 Phase 4
9 Optimizing the Use of Vasopressor After Coronary Reperfusion in Cardiogenic Shock Secondary to Myocardial Infarction. Pathophysiological Study Comparing the Efficacy and Cardio-circulatory Tolerability of Epinephrine and Norepinephrine Completed NCT01367743 Phase 4 epinephrine perfusion;norepinephrine perfusion
10 Comparison of Milrinone Versus Dobutamine in a Heterogeneous Population of Critically Ill Patients Completed NCT03207165 Phase 4 Milrinone;Dobutamine
11 Safety and Efficacy of Levosimendan in Patients With Acute Myocardial Infarction Complicated by Symptomatic Left Ventricular Failure. Completed NCT00324766 Phase 4 levosimendan;placebo,
12 Early Intra-aortic Balloon Pump Placement in Acute Decompensated Heart Failure Complicated by Cardiogenic Shock: a Randomized Clinical Trial Recruiting NCT04369573 Phase 4
13 Cangrelor Versus Ticagrelor In Patients With Acute Myocardial Infarction Complicated With Initial Cardiogenic Shock Recruiting NCT03551964 Phase 4 Cangrelor;Ticagrelor
14 CAPITAL DOREMI 2: Inotrope Versus Placebo Therapy for Cardiogenic Shock Recruiting NCT05267886 Phase 4 Dobutamine;Milrinone;Normal Saline
15 REvaSCUlarization StratEgy of Multivessel Coronary Artery Disease for Patients With Acute Myocardial Infarction Complicated by Cardiogenic SHOCK Undergoing Veno-arterial Extracorporeal Membrane Oxygenator: Randomized-Controlled Trial (RESCUE-SHOCK) Not yet recruiting NCT05527717 Phase 4
16 Clinical Outcome and Cost-effectiveness of Reduced Noradrenaline by Using a Lower Blood Pressure Target in Patients With Cardiogenic Shock From Acute Myocardial Infarction Not yet recruiting NCT05168462 Phase 4 Reduced noradrenaline use
17 National Multicenter Randomized Trial, Comparing Two Treatments of Myocardial Infarction Complicated With Cardiogenic Shock: Standard Treatment vs Standard Treatment Plus ECLS (Extracorporeal Life Support) Terminated NCT00314847 Phase 4
18 Prospective Comparison of ARNI to Alternate Oral Vasodilator Therapies to Determine the Hemodynamic Profile and Relative Tolerability of (ARNIs) in Patients With Decompensated Heart Failure and Low Cardiac Output Withdrawn NCT04206865 Phase 4 Sacubitril-Valsartan;Standard Oral Vasodilators
19 Norepinephrine vs Norepinephrine and Dobutamine in Cardiogenic Shock : a Randomised, Opened, Cross-over Study. Heart SHOCK-NORDOB Study Unknown status NCT03340779 Phase 3 Norepinephrine
20 Adjunctive Mild Hypothermia Therapy to Primary Percutaneous Coronary Intervention in Patients With Acute Myocardial Infarction Complicated With Shock: A Feasibility Study Unknown status NCT00846222 Phase 3
21 Efficacy of Levosimendan in the Critically Ill Patients With Unstable Hemodynamics (the LICI Study) - A Double Blind Randomized Pilot Study Unknown status NCT00093301 Phase 2, Phase 3 Levosimendan;Dobutamine
22 Shock Trial: Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock. Completed NCT00000552 Phase 3 thrombolytic therapy
23 Investigator-initiated, Placebo-controlled, Double-blind, Multi-center, Randomized Trial to Assess the Efficacy and Safety of Adrecizumab in Subjects With Cardiogenic Shock Completed NCT03989531 Phase 2, Phase 3 Placebo
24 Effects of Adding Ivabradine in Patients With Cardiogenic Shock Requiring Inotropic Support Recruiting NCT05594342 Phase 3 Ivabradine 7.5Mg Tab;DOBUTamine Injectable Solution
25 Low Dose of Hydrocortisone and Fludrocortisone in Adult Cardiogenic Shock. A Multicenter, Prospective, Double-blind, Randomized, Placebo-controlled Study Recruiting NCT03773822 Phase 3
26 LEVOSIMENDAN to Facilitate Weaning From ECMO in Severe Cardiogenic Shock Patients Recruiting NCT04728932 Phase 3 Levosimendan;Placebo of Levosimendan
27 Effect of Early Use of Levosimendan Versus Placebo on Top of a Conventional Strategy of Inotrope Use on a Combined Morbidity-mortality Endpoint in Patients With Cardiogenic Shock Not yet recruiting NCT04020263 Phase 3 Levosimendan 2.5 MG/ML Injectable Solution;Placebo
28 Normoxemic Versus Hyperoxemic Extracorporeal Oxygenation : Impact on Organ Dysfunction in Patients Supported by Veino-arterial ECMO for Cardiogenic Shock Not yet recruiting NCT04990349 Phase 3 Oxygen gas
29 A Phase III International, Multi-Center, Prospective, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Nitric Oxide Synthase Inhibition With Tilarginine Acetate Injection in Patients With Cardiogenic Shock Complicating Acute Myocardial Infarction, or the TRIUMPH Trial Terminated NCT00112281 Phase 3 Tilarginine Acetate Injection intravenous infusion
30 Phase II Clinical Trial for a Stepwise Progression in the Treatment of Cardiogenic Shock Completed NCT02591771 Phase 2 adrenaline
31 Effects of Pyruvate in Patients With Cardiogenic Shock and Intra-aortic Balloon Counterpulsation Completed NCT00604331 Phase 2 Pyruvate
32 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study on the Safety and Efficacy of Istaroxime for Pre-Cardiogenic Shock Recruiting NCT04325035 Phase 2 Istaroxime;Placebo
33 Low-dose Dobutamine Infusion and Single-dose Tocilizumab in Acute Myocardial Infarction Patients With High Risk of Cardiogenic Shock Development - a 2x2 Multifactorial, Double-blinded, Randomized, Placebo Controlled Trial Recruiting NCT05350592 Phase 2 Tocilizumab;Dobutamine;NaCl 0.9%
34 Heparin Requirement in Counterpulsation Terminated NCT00445211 Phase 2 Heparin
35 Cyclosporine in Acute Myocardial Infarction Complicated by Cardiogenic Shock Withdrawn NCT01901471 Phase 2 Single bolus of Placebo of CicloMulsion® (Neurovive).;Single bolus of cyclosporine A (CicloMulsion®, Neurovive)
36 Use of Transtoracic Ecocargiogram With Calculation of Left Ventricular Volume Index in the Initial Adjustment of Initial Dose of Dobutamine in Patients With Heart Failure and Cardiogenic Shock Unknown status NCT03727282
37 SMart Angioplasty Research Team: A Multi-center, Open, REtrospective and Prospective Observational Study to Investigate Clinical oUtcomes and Efficacy of Left Ventricular Assist Device for Korean Patients With Cardiogenic Shock : RESCUE Unknown status NCT02985008
38 Levosimendan and Global Longitudinal Strain Assessment in Cardiogenic Shock Sepsis (GLASSES 1): a Study Protocol for an Observational Study Unknown status NCT04141410 Levosimendan
39 Hemodynamic Assessment in Cardiogenic Shock Regarding the Etiology Unknown status NCT03283995
40 Registry for Cardiogenic Shock: Utility and Efficacy of Device Therapy Unknown status NCT02790242
41 Prognostic Value of Circulating microRNAs in Patients With ST-elevation Myocardial Infarction (STEMI) Complicated by Cardiogenic Shock Unknown status NCT02691286
42 Use of Percutaneous Mitral Leaflet Approach for Severe Mitral Regurgitation in Cardiogenic Shock: Results From a Multicenter Observational Italian Experience (the Mitra-Shock Study). Unknown status NCT04399499
43 The Effects of Intra Aortic Balloon Pump Prior to Revascularization on Mortality of Patients With Acute Coronary Syndrome Complicated With Cardiogenic Shock Unknown status NCT03635840
44 Cardiogenic Shock Intravascular Cooling Trial (CHILL-SHOCK) Unknown status NCT03141255
45 Vasoplegia During VA-ECMO for Refractory Cardiogenic Shock : Descriptive Analysis of a Retrospective Cohort Unknown status NCT03968926
46 The Effect of Simultaneous Renal Replacement Therapy on Extracorporeal Membrane Oxygenation Support for Cardiogenic Shock Patients Unknown status NCT02870946
47 Levosimendan Efficacy for Veno-arterial ECMO Weaning: a Retrospective Study Unknown status NCT03346824
48 Post-Cardiotomy Extra-Corporeal Life Support Study: a Retrospective International Multicenter Cohort Study Unknown status NCT03857217
49 A Randomized, Controlled Trial: Hemoperfusion in Extracorporeal Membrane Oxygenation (ECMO) Patients Unknown status NCT03729765
50 Skeletal Muscle Oxygenation in Critically Ill Unknown status NCT00384644

Search NIH Clinical Center for Cardiogenic Shock

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Digitalis preparation
DIGITALIS,POWDERED
Digitoxin
Digoxin
Glucagon
Inamrinone
inamrinone lactate

Genetic Tests for Cardiogenic Shock

Anatomical Context for Cardiogenic Shock

Organs/tissues related to Cardiogenic Shock:

MalaCards : Heart, Skeletal Muscle, Kidney, Liver, Lung, Spinal Cord, Atrioventricular Node

Publications for Cardiogenic Shock

Articles related to Cardiogenic Shock:

(show top 50) (show all 13971)
# Title Authors PMID Year
1
Cardiac troponin I levels in acute pulmonary embolism. 53 62
20222345 2009
2
Impaired plasma B-type natriuretic peptide clearance in human septic shock. 53 62
18679125 2008
3
Excimer laser in myocardial infarction: a comparison between STEMI patients with established Q-wave versus patients with non-STEMI (non-Q). 53 62
17426922 2008
4
B-type natriuretic peptide and its molecular precursor in myocardial infarction complicated by cardiogenic shock. 53 62
17448415 2007
5
Time-to-reperfusion therapy influences outcome of patients with myocardial infarction subjected to facilitated PCI. 53 62
19758922 2005
6
Natriuretic peptides and E-selectin as predictors of acute deterioration in patients with inotrope-dependent heart failure. 53 62
15848333 2005
7
Plasma brain natriuretic peptide reflects left ventricular function during percutaneous cardiopulmonary support. 53 62
14726055 2004
8
Quantitative measurement of the novel human plasma protein, IHRP, by sandwich ELISA. 53 62
11256472 2001
9
Frequency and clinical outcome of cardiogenic shock during acute myocardial infarction among patients receiving reteplase or alteplase. Results from GUSTO-III. Global Use of Strategies to Open Occluded Coronary Arteries. 53 62
10099909 1999
10
Impact of time to treatment with tissue plasminogen activator on morbidity and mortality following acute myocardial infarction (The second National Registry of Myocardial Infarction). 53 62
9708650 1998
11
[Factors predictive of early mortality after acute myocardial infarction]. 53 62
8953932 1996
12
Impella Versus Extracorporeal Membranous Oxygenation (ECMO) for Cardiogenic Shock: A Systematic Review and Meta-analysis. 62
36174742 2023
13
Echocardiographic Characteristics of Cardiogenic Shock Patients with and Without Cardiac Arrest. 62
35656768 2023
14
The critical care literature 2021. 62
36306647 2023
15
Risk of complications after a non-ST segment elevation acute myocardial infarction in a Latin-American cohort: An application of the ACTION ICU score. 62
36183629 2023
16
Correlation between severity of obesity and mortality in cardiogenic shock. 62
36084397 2023
17
How does protocolization improve outcomes in cardiogenic shock due to end-stage heart failure? 62
35931208 2022
18
Comment: Analysis of Bicarbonate-Based Purge Solution in Patients With Cardiogenic Shock Supported Via Impella Ventricular Device. 62
36458676 2022
19
Trends in Veno-Arterial Extracorporeal Life Support With and Without an Impella or Intra-Aortic Balloon Pump for Cardiogenic Shock. 62
36420809 2022
20
Imaging for Transcatheter Mitral Valve Edge-to-Edge Repair for an Unusual Cause of Cardiogenic Shock. 62
36458532 2022
21
Phenotyping and Hemodynamic Assessment in Cardiogenic Shock: From Physiology to Clinical Application. 62
36335176 2022
22
Author's response: "Peripheral blood neutrophil-to-lymphocyte ratio is associated with mortality across the spectrum of cardiogenic shock severity". 62
35105481 2022
23
Letter to the Editor: "Peripheral blood neutrophil-to-lymphocyte ratio is associated with mortality across the spectrum of cardiogenic shock severity". 62
35101338 2022
24
Cardiogenic Shock: Searching for a Better Lifeboat. 62
36420811 2022
25
Parameters associated with successful weaning of veno-arterial extracorporeal membrane oxygenation: a systematic review. 62
36471408 2022
26
Impella Versus Intra-Aortic Balloon Pump for High-Risk PCI: A Propensity-Adjusted Large-Scale Claims Dataset Analysis. 62
36210212 2022
27
Corrigendum to "Venoarterial extracorporeal membrane oxygenation flow or dobutamine to improve microcirculation during ECMO for refractory cardiogenic shock" [Journal of Critical Care 71 (2022) Start page 1 - End page 1 /154090]. 62
36436880 2022
28
Inotropes, vasopressors, and mechanical circulatory support for treatment of cardiogenic shock complicating myocardial infarction: a systematic review and network meta-analysis. 62
36195825 2022
29
Cardiogenic shock due to yew poisoning rescued by VA-ECMO: case report and literature review. 62
35942511 2022
30
Pharmacological treatment of cardiogenic shock - A state of the art review. 62
35697151 2022
31
Use of extracorporeal membrane oxygenation in massive amlodipine overdose. 62
35986754 2022
32
Distinctive kidney function trajectories following left ventricular assist device implantation. 62
36182652 2022
33
Heart Failure After Right Ventricular Myocardial Infarction. 62
36197627 2022
34
Outcomes of isolated CABG from "OPCAB favor institution" for patients with left ventricular dysfunction. 62
36462143 2022
35
Outcomes of Urgent Interhospital Transportation for Extracorporeal Membrane Oxygenation Patients. 62
36348506 2022
36
Implementation of an Electronic Health Records-Based Safe Contrast Limit for Preventing Contrast-Associated Acute Kidney Injury After Percutaneous Coronary Intervention. 62
36475471 2022
37
Impact of ventricular arrhythmia on LVAD implantation admission outcomes. 62
35943857 2022
38
Mechanical Complications of Myocardial Infarction. 62
36075485 2022
39
Oxygen Therapy Confers Little Benefit in Patients with Acute ST-Segment Elevation Myocardial Infarction: A Systematic Review and Meta-Analysis. 62
36455144 2022
40
Clinician and Algorithmic Application of the 2019 and 2022 Society of Cardiovascular Angiography and Intervention Shock Stages in the Critical Care Cardiology Trials Network Registry. 62
36458542 2022
41
Surgically Implanted Impella Device for Patients on Impella CP Support Experiencing Refractory Hemolysis. 62
35348311 2022
42
Decreased Heart Rate Variability in COVID-19. 62
36471860 2022
43
A Successful Case of Cardiac Arrest due to Acute Myocarditis with COVID-19: 120 Minutes on Manual Cardiopulmonary Resuscitation then Veno-Arterial Extracorporeal Membrane Oxygenation. 62
36193699 2022
44
Clinical characteristics of patients with cardiac arrest induced by pesticide poisoning: Analysis of 15 cases. 62
36089421 2022
45
Contemporary Management of Concomitant Cardiac Arrest and Cardiogenic Shock Complicating Myocardial Infarction. 62
36464466 2022
46
Predictors and Hospital Outcomes in Pregnant Patients Undergoing Extracorporeal Membrane Oxygenation: A Nationwide Study. 62
36384013 2022
47
Safety and usefulness of left ventricular endomyocardial biopsy in new- onset acute heart failure requiring mechanical support by an Impella® device. 62
35944774 2022
48
In-hospital mortality of COVID-19 patients hospitalized with ST-segment elevation myocardial infarction: A meta-analysis. 62
36411872 2022
49
Cardiovascular outcomes of transradial versus transfemoral percutaneous coronary intervention in End-Stage renal Disease: A Regression-Based comparison. 62
36051245 2022
50
Comparison of Pre- and Postnatally Diagnosed Coronary Artery Fistulae: Echocardiographic Features and Clinical Outcomes. 62
35940444 2022

Variations for Cardiogenic Shock

Expression for Cardiogenic Shock

Search GEO for disease gene expression data for Cardiogenic Shock.

Pathways for Cardiogenic Shock

Pathways related to Cardiogenic Shock according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.32 NPPB NPPA
2 10.6 NPPB NPPA
3 9.97 NPPB NPPA

GO Terms for Cardiogenic Shock

Cellular components related to Cardiogenic Shock according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 collagen-containing extracellular matrix GO:0062023 9.02 PLAT NPPA ITIH4

Biological processes related to Cardiogenic Shock according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 vasodilation GO:0042311 9.73 NPPB NPPA
2 platelet-derived growth factor receptor signaling pathway GO:0048008 9.71 PLAT PIK3C2A
3 cGMP-mediated signaling GO:0019934 9.62 NPPB NPPA
4 cardiac conduction system development GO:0003161 9.56 NPPB NPPA
5 blood vessel diameter maintenance GO:0097746 9.54 NPPB NPPA
6 negative regulation of systemic arterial blood pressure GO:0003085 9.46 NPPB NPPA
7 cGMP biosynthetic process GO:0006182 9.26 NPPB NPPA
8 receptor guanylyl cyclase signaling pathway GO:0007168 8.92 NPPB NPPA

Molecular functions related to Cardiogenic Shock according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signaling receptor binding GO:0005102 9.43 PLAT NPPB NPPA
2 hormone receptor binding GO:0051427 8.92 NPPB NPPA

Sources for Cardiogenic Shock

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....